{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022604","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.236969+00:00","generated_at":"2026-05-16T19:52:57.748068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M","bullets":["Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.","CyPath Lung testing revenue increased 122% YoY; test volumes up 97% in first nine months of 2025.","Net loss $5.1M ($4.74 per share) compared to $2.0M loss ($4.84 per share) in Q3 2024, driven by change in fair value of warrants.","Raised $10.4M gross proceeds from equity transactions; cash and equivalents increased to $7.7M from $1.1M at year-end 2024.","Appointed Roberto Rios and John J. Oppenheimer to board; regained full Nasdaq compliance for listing of BIAF and BIAFW."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022604","json":"https://secwatch.observer/filing/0001493152-25-022604.json","markdown":"https://secwatch.observer/filing/0001493152-25-022604.md","text":"https://secwatch.observer/filing/0001493152-25-022604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/0001493152-25-022604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:52:57.748068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}